Compile Data Set for Download or QSAR
Report error Found 146 Enz. Inhib. hit(s) with all data for entry = 1277
TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283463(US10023557, Example 115 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283462(US10023557, Example 114 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283465(US10023557, Example 117 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283464(US10023557, Example 116 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283467(US10023557, Example 119 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283466(US10023557, Example 118 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283469(US10023557, Example 121 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283468(US10023557, Example 120 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283454(US10023557, Example 107 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283456(US10023557, Example 108 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283459(US10023557, Example 111 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283458(US10023557, Example 110 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283461(US10023557, Example 113 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283460(US10023557, Example 112 | N-((6-amino-2-methylpyri...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283479(US10023557, Example 131 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283478(US10023557, Example 130 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283481(US10023557, Example 133 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283480(US10023557, Example 132 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283484(US10023557, Example 136 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283471(US10023557, Example 123 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283470(US10023557, Example 122 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283473(US10023557, Example 125 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283472(US10023557, Example 124 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283475(US10023557, Example 127 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283474(US10023557, Example 126 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283476(US10023557, Example 128 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM314643(N-((1-aminoisoquinolin-6-yl)methyl)-2-((7- chloroq...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283486(US10023557, Example 138 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283489(US10023557, Example 141 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283488(US10023557, Example 140 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283491(US10023557, Example 143 | N-((3-chloro-6-fluoro-1H...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283490(US10023557, Example 142 | N-((1-aminoisoquinolin-6...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283493(US10023557, Example 145 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283492(US10023557, Example 144 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283351(US10023557, Example 3 | N-((1-aminoisoquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283353(US10023557, Example 5 | N-((3-chloro-6-fluoro-1H-i...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283355(US10023557, Example 7 | N-((6-amino-2,4-dimethylpy...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283354(US10023557, Example 6 | N-((1-aminoisoquinolin-6-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283367(US10023557, Example 19 | N-((3-chloro-1H-pyrrolo[2...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283366(US10023557, Example 18 | N-((6-fluoro-1H-indol-5-y...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283369(US10023557, Example 21 | N-((3-chloro-4-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283368(US10023557, Example 20 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283360(US10023557, Example 12 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283363(US10023557, Example 15 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283365(US10023557, Example 17 | N-((3-chloro-6-fluoro-1H-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283364(US10023557, Example 16 | N-((1-aminoisoquinolin-6-...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283383(US10023557, Example 35 | N-((6-amino-2,4-dimethylp...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283385(US10023557, Example 37 | N-((5-chloro-1H-indazol-3...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Lifesci Pharmaceuticals

US Patent
LigandPNGBDBM283382(US10023557, Example 34 | N-((6-amino-2-methylpyrid...)
Affinity DataIC50: 100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/29/2019
Entry Details
US Patent

Displayed 1 to 50 (of 146 total ) | Next | Last >>
Jump to: